Immediate Impact

1 from Science/Nature 68 standout
Sub-graph 1 of 23

Citing Papers

NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
2 intermediate papers

Works of Umberto Conte being referenced

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
2023
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
2023
and 1 more

Author Peers

Author Last Decade Papers Cites
Umberto Conte 59 101 142 150 25 333
Nicola Susca 24 106 77 78 20 294
Shun Iida 53 115 49 46 32 326
L Lemaître 20 59 70 134 21 337
Mónica Enguita‐Germán 30 81 100 148 19 330
Abdelmonem Elhosseiny 30 55 105 42 19 329
Haoran Zhang 27 82 82 56 37 264
Young Bae Choi 90 52 63 40 35 294
Maxime Chénard-Poirier 34 141 173 77 29 340
Naohiro Uchida 34 51 173 121 32 357
Sara R. Rashkin 33 129 85 42 15 361

All Works

Loading papers...

Rankless by CCL
2026